The Impact of Iron Chelators on the Biology of Cancer Stem Cells

The Impact of Iron Chelators on the Biology of Cancer Stem Cells

Neoplastic diseases are still a major medical challenge, requiring a constant search for new therapeutic options. A serious problem of many cancers is resistance to anticancer drugs and disease progression in metastases or local recurrence. These characteristics of cancer cells may be related to the...

Full description

Bibliographic Details
Main Authors:	Julia Szymonik, Kamila Wala, Tomasz Górnicki, Jolanta Saczko, Bartosz Pencakowski, Julita Kulbacka
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	International Journal of Molecular Sciences
Subjects:	cancer stem cells stemness markers iron chelators deferoxamine deferasirox
Online Access:	https://www.mdpi.com/1422-0067/23/1/89

Similar Items

Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01)

Challenges of Iron Chelation in Thalassemic Children
by: Alkistis Adramerina, et al.
Published: (2024-02-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

Development of Thalassemia Medication Questionnaire (TMQ): An Instrument for Measuring Major Thalassemia Patients’ Knowledge and Practice Regarding their Medications
by: Azita Azarkeivan, et al.
Published: (2022-12-01)

Iron and Acinetobacter baumannii Biofilm Formation
by: Valentina Gentile, et al.
Published: (2014-08-01)

Combination therapies in iron chelation
by: Raffaella Origa
Published: (2014-12-01)

Comparison of the Mean Serum Ferritin Levels in Thalassaemia Major Patients after Giving Deferasirox and Deferoxamine
by: Seema Aftab, et al.
Published: (2017-12-01)

Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
by: Bayanzay K, et al.
Published: (2016-08-01)

Recent developments centered on orally active iron chelators
by: Robert Hider
Published: (2014-09-01)

Iron chelating agents for iron overload diseases
by: Guido Crisponi, et al.
Published: (2014-09-01)

Emerging Roles of the Iron Chelators in Inflammation
by: Alessandra Di Paola, et al.
Published: (2022-07-01)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
by: Raffaella Origa, et al.
Published: (2022-04-01)

Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells
by: Chiara Calabrese, et al.
Published: (2020-10-01)

Sobrecarga e quelação de ferro na anemia falciforme Iron overload and iron chelation in sickle cell disease
by: Rodolfo D. Cançado
Published: (2007-09-01)

Adherence to Iron Chelation Therapy and Its Determinants
by: Sukhmani Sidhu, et al.
Published: (2021-01-01)

Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats
by: Yunfei Feng, et al.
Published: (2023-08-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs
by: George J. Kontoghiorghes
Published: (2021-07-01)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
by: Chalmers AW, et al.
Published: (2016-02-01)

A Young Adult with Unintentional Acute Parenteral Iron intoxication Treated with Oral Chelation: The Use of Liver Ferriscan.
by: Vincenzo De Sanctis
Published: (2017-01-01)

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2020-07-01)

Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators
by: Seung Hun Park, et al.
Published: (2022-05-01)

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE
by: Jialian Li
Published: (2020-04-01)

ECONOMIC EVALUATION OF CHELATION REGIMENS FOR β--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW
by: Jialian Li
Published: (2019-06-01)

Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19?
by: Parisa Ghasemiyeh, et al.
Published: (2020-06-01)

A Deferasirox Derivative That Acts as a Multifaceted Platform for the Detection and Quantification of Fe<sup>3+</sup>
by: Axel Steinbrueck, et al.
Published: (2021-03-01)

Naringin is a promising natural compound for therapy of iron-overload disorders
by: Mehrdad Jahanshahi, et al.
Published: (2022-07-01)

Deferoxamine-Based Materials and Sensors for Fe(III) Detection
by: Giancarla Alberti, et al.
Published: (2022-11-01)

The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity
by: Masanari Umemura, et al.
Published: (2017-08-01)

Comparison of the Effects of Deferasirox (Nanojade®) and Deferoxamine (Desferal®) on Serum Ferritin Level Changes in Major Beta-Thalassemia Patients: A Randomized Clinical Trial
by: saeedeh Khorashadi Zadeh, et al.
Published: (2023-12-01)

Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia
by: Rasul Jameel Ali, et al.
Published: (2020-12-01)

Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?
by: Jan O. Aaseth, et al.
Published: (2022-11-01)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
by: Maria Lazaridou, et al.
Published: (2020-03-01)

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
by: Ali T. Taher, et al.
Published: (2018-11-01)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
by: Hana Votavova, et al.
Published: (2021-01-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
by: Monica Pinheiro de Almeida Verissimo, et al.
Published: (2013-01-01)

An overview of complications associated with deferoxamine therapy in thalassemia
by: Bijan Keikhaei, et al.
Published: (2021-01-01)

Drugs That Mimic Hypoxia Selectively Target EBV-Positive Gastric Cancer Cells
by: Blue-leaf A. Cordes, et al.
Published: (2023-03-01)

Treatment Status of Patients with Β-Thalassemia Major in Northern Iran: Thalassemia Registry System
by: Mehrnoush KOSARYAN, et al.
Published: (2019-07-01)